CONTEXT: The co-occurrence of insulin resistance (IR) and hypertension is a heritable condition leading to cardiovascular complications. Caveolin-1 (CAV1), a gene previously associated with metabolic dysfunction in animal and cellular models, may be a marker for these conditions in humans. OBJECTIVE: The objective of the study was to examine the relationship between CAV1 variants and IR in two hypertensive cohorts and to corroborate the findings in a CAV1 knockout mouse. DESIGN, SETTING, AND PARTICIPANTS: A candidate gene association study was conducted in two hypertensive cohorts: 1) Caucasian and 2) Hispanic. Multivariate associations between individual variants and insulin-resistant phenotypes were analyzed, accounting for age, gender, body mass index, and sibling relatedness. Intraperitoneal glucose tolerance tests were conducted in wild-type and CAV1 knockout mice. RESULTS: In the Caucasian hypertensive cohort, minor allele carriers of two CAV1 single-nucleotide polymorphisms (rs926198, rs3807989) had significantly higher fasting insulin levels (P = 0.005, P = 0.007), increased homeostatic assessment model for insulin resistance (HOMA-IR) (P =0.005, P = 0.008), and decreased M value during hyperinsulinemic, euglycemic clamp procedure (P = 0.004, P = 0.05) than major allele homozygotes. Findings were replicated in the Hispanic hypertensive cohort cohort for fasting insulin levels (P = 0.005, P = 0.02) and HOMA-IR (P = 0.008 and P = 0.02). Meta-analysis demonstrated significant associations of both single-nucleotide polymorphisms with fasting insulin levels (P = 0.00008, P = 0.0004) and HOMA-IR (P = 0.0001, P = 0.0004). As compared with wild type, CAV1 knockout mice displayed higher blood pressure levels and higher fasting glucose, insulin, and HOMA-IR levels and an exaggerated glycemic response to a glucose challenge. CONCLUSION: Variations in the CAV1 gene are associated with IR and hypertension. CAV1 gene polymorphisms may be a biomarker for IR and hypertension, enabling earlier detection and improved treatment strategies.
CONTEXT: The co-occurrence of insulin resistance (IR) and hypertension is a heritable condition leading to cardiovascular complications. Caveolin-1 (CAV1), a gene previously associated with metabolic dysfunction in animal and cellular models, may be a marker for these conditions in humans. OBJECTIVE: The objective of the study was to examine the relationship between CAV1 variants and IR in two hypertensive cohorts and to corroborate the findings in a CAV1 knockout mouse. DESIGN, SETTING, AND PARTICIPANTS: A candidate gene association study was conducted in two hypertensive cohorts: 1) Caucasian and 2) Hispanic. Multivariate associations between individual variants and insulin-resistant phenotypes were analyzed, accounting for age, gender, body mass index, and sibling relatedness. Intraperitoneal glucose tolerance tests were conducted in wild-type and CAV1 knockout mice. RESULTS: In the Caucasian hypertensive cohort, minor allele carriers of two CAV1 single-nucleotide polymorphisms (rs926198, rs3807989) had significantly higher fasting insulin levels (P = 0.005, P = 0.007), increased homeostatic assessment model for insulin resistance (HOMA-IR) (P =0.005, P = 0.008), and decreased M value during hyperinsulinemic, euglycemic clamp procedure (P = 0.004, P = 0.05) than major allele homozygotes. Findings were replicated in the Hispanic hypertensive cohort cohort for fasting insulin levels (P = 0.005, P = 0.02) and HOMA-IR (P = 0.008 and P = 0.02). Meta-analysis demonstrated significant associations of both single-nucleotide polymorphisms with fasting insulin levels (P = 0.00008, P = 0.0004) and HOMA-IR (P = 0.0001, P = 0.0004). As compared with wild type, CAV1 knockout mice displayed higher blood pressure levels and higher fasting glucose, insulin, and HOMA-IR levels and an exaggerated glycemic response to a glucose challenge. CONCLUSION: Variations in the CAV1 gene are associated with IR and hypertension. CAV1 gene polymorphisms may be a biomarker for IR and hypertension, enabling earlier detection and improved treatment strategies.
Authors: A H Xiang; S P Azen; L J Raffel; S Tan; L S Cheng; J Diaz; E Toscano; P C Henderson; H N Hodis; W A Hsueh; J I Rotter; T A Buchanan Journal: Circulation Date: 2001-01-02 Impact factor: 29.690
Authors: Alex W Cohen; Babak Razani; Xiao Bo Wang; Terry P Combs; Terence M Williams; Philipp E Scherer; Michael P Lisanti Journal: Am J Physiol Cell Physiol Date: 2003-03-26 Impact factor: 4.249
Authors: Steven C Hunt; R Curtis Ellison; Larry D Atwood; James S Pankow; Michael A Province; Mark F Leppert Journal: Hypertension Date: 2002-07 Impact factor: 10.190
Authors: M Iwanishi; T Haruta; Y Takata; O Ishibashi; T Sasaoka; K Egawa; T Imamura; K Naitou; T Itazu; M Kobayashi Journal: Diabetologia Date: 1993-05 Impact factor: 10.122
Authors: Luminita H Pojoga; Jose R Romero; Tham M Yao; Paul Loutraris; Vincent Ricchiuti; Patricia Coutinho; Christine Guo; Nathalie Lapointe; James R Stone; Gail K Adler; Gordon H Williams Journal: Endocrinology Date: 2010-01-22 Impact factor: 4.736
Authors: Luminita H Pojoga; Tham M Yao; Lauren A Opsasnick; Waleed T Siddiqui; Ossama M Reslan; Gail K Adler; Gordon H Williams; Raouf A Khalil Journal: J Pharmacol Exp Ther Date: 2015-07-16 Impact factor: 4.030
Authors: Rene Baudrand; Mark O Goodarzi; Anand Vaidya; Patricia C Underwood; Jonathan S Williams; Xavier Jeunemaitre; Paul N Hopkins; Nancy Brown; Benjamin A Raby; Jessica Lasky-Su; Gail K Adler; Jinrui Cui; Xiuqing Guo; Kent D Taylor; Yii-Der I Chen; Anny Xiang; Leslie J Raffel; Thomas A Buchanan; Jerome I Rotter; Gordon H Williams; Luminita H Pojoga Journal: Metabolism Date: 2015-09-12 Impact factor: 8.694
Authors: Alexander W Krug; Eric Tille; Bei Sun; Luminita Pojoga; Jonathan Williams; Bindu Chamarthi; Andrew H Lichtman; Paul N Hopkins; Gail K Adler; Gordon H Williams Journal: Age (Dordr) Date: 2012-10-02
Authors: Luminita H Pojoga; Tham M Yao; Lauren A Opsasnick; Amanda E Garza; Ossama M Reslan; Gail K Adler; Gordon H Williams; Raouf A Khalil Journal: J Pharmacol Exp Ther Date: 2013-11-26 Impact factor: 4.030
Authors: Gabriela Montenegro de Souza; Maria Eduarda de Albuquerque Borborema; Thays Maria Costa de Lucena; Ariane Fernandes da Silva Santos; Brenda Regina de Lima; Dinaldo Cavalcanti de Oliveira; Jaqueline de Azevêdo Silva Journal: Mol Biol Rep Date: 2020-10-29 Impact factor: 2.316